Methods and compositions for treating pulmonary hypertension
Formulating treprostinil with diketopiperazine into dry powder compositions addresses the delivery challenges of PAH treatments, enabling rapid and stable inhalation therapy with improved efficacy.
Patent Information
- Application Number
- JP2024525356
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-27
- Filing Date
- 2022-10-27
- Publication Date
- 2024-11-13
AI Technical Summary
Current treatments for pulmonary arterial hypertension (PAH) face challenges in delivering drugs like treprostinil effectively due to their hygroscopic, hydrophobic, and temperature-sensitive properties, making formulation difficult and unstable, especially for inhalation therapies.
Formulating treprostinil and its derivatives into dry powder compositions using diketopiperazine, which are prepared through specific methods involving high-shear mixing, washing, and freeze-drying to create crystalline particles, allowing for rapid and stable delivery via dry powder inhalers.
The method enables rapid delivery of treprostinil to the lungs within seconds, achieving therapeutic concentrations in less than 30 minutes, with improved stability and efficacy compared to traditional nebulization methods.
Smart Images

Figure 2024541985000009 
Figure 2024541985000010 
Figure 2024541985000011
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 63 / 272,467, filed October 27, 2021, the entire contents of which are incorporated herein by reference.
[0002] (Technical field) Disclosed are inhalable compositions comprising treprostinil and a diketopiperazine, methods of making and methods of using the compositions to treat pulmonary diseases, particularly pulmonary arterial hypertension and idiopathic pulmonary diseases. [Background technology]
[0003] Pulmonary arterial hypertension (PAH) is a complex, multifactorial, progressive syndrome characterized by persistently elevated pulmonary artery pressure and pulmonary vascular resistance (PVR) that leads to elevated right ventricular afterload and ultimately right heart failure. Right ventricular failure limits cardiac output during exertion. The most common symptoms at onset are shortness of breath, fatigue, sore throat, syncope, and abdominal distension, and reduced exercise capacity characterizes the disease.
[0004] Currently, there are various methods of treating PAH using tablets, nebulizers, injections, and pumps to alleviate the symptoms of the disease, but it would be advantageous to provide patients suffering from PAH with a simple and effective way to obtain medications. Therefore, new medications and methods for treating PAH are needed to facilitate the administration of these products to patients.
[0005] Drug delivery to pulmonary tissues has been achieved using a variety of inhalation devices, including nebulizers and inhalers such as metered dose inhalers and dry powder inhalers for treating localized diseases or disorders. The delivery of powder formulations via inhalers can be more or less straightforward, depending on the type of compound being formulated and the type of inhaler being used. Some other compounds are more difficult to deliver due to certain properties, such as hygroscopicity, hydrophobicity, temperature sensitivity, or temperature resistance, and are difficult to combine with certain pharma- ceutically acceptable carriers and / or excipients due to stability, insolubility, viscosity, and other inherent chemical characteristics. Compounds that are difficult to formulate and difficult to solubilize include prostacyclin derivatives and salts, including prostacyclin and treprostinil. Thus, the new method for formulating drugs for the treatment of diseases is stable and can maintain therapeutically effective activity, preferably at room temperature, and can be stored for long periods of time. Summary of the Invention [Means for solving the problem]
[0006] Disclosed is a method for facilitating the formulation of prostacyclin and prostacyclin analogs, including treprostinil and its derivatives, into dry powder compositions for inhalation and deep lung delivery.For example, disclosed is that the dry powder compositions containing treprostinil, or its derivatives, or combinations thereof, can be used to treat diseases, including pulmonary arterial hypertension and / or idiopathic pulmonary fibrosis.
[0007] In one embodiment, a method for producing a dry powder composition comprising a hydrophobic compound includes preparing a suspension of a dry powder composition comprising crystalline particles of diketopiperazine, including (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine, and an acetic acid solution at a temperature ranging from 13° C. to about 20° C. while mixing the suspension in a high shear mixer, washing the suspension with water, pelletizing the suspension in a freeze granulator, and drying the suspension in a freeze dryer to recover the crystalline particles of diketopiperazine. In this embodiment, the method includes resuspending the dry powder containing the dry crystalline particles of diketopiperazine in a solution of deionized water and alcohol to contain about 0.5% to about 2% solids in the suspension, or about 1% to about 4% solids in the suspension, or about 1% to about 10% solids in the suspension, or more than 10%, preparing a solution containing treprostinil in dilute aqueous ethanol or absolute ethanol, mixing the solution containing treprostinil with the crystalline particles of diketopiperazine in the suspension, and spray drying the suspension to form a dry powder composition. In one embodiment, the method includes adding more ethanol to the suspension to achieve an ethanol / water density close to that of treprostinil, thereby reducing the buoyancy of the treprostinil and dispersing it more uniformly in the suspension.
[0008] Also disclosed is a method of using the composition in the treatment of pulmonary hypertension. In an embodiment herein, the method comprises providing a treprostinil composition in a dry powder inhaler that includes a replaceable single-dose cartridge that includes a dry powder for inhalation for delivery to the lungs for local delivery to the pulmonary circulation or systemic delivery. Dry powder inhalers are compact, reusable or disposable, breath-powered inhalers that come in a variety of shapes and sizes and include a system of airflow conduits for effective and rapid delivery of powdered drug to the lungs and systemic circulation. In one embodiment, the dry powder composition for inhalation that includes treprostinil or a salt thereof is provided to the respiratory system in less than 10 seconds, or less than 5 seconds, or less than 3 seconds, and treprostinil is detected in peak concentrations in the blood of treated subjects in less than 30 minutes, with a median Tmax (treprostinil maximum) of about 10 minutes or less.
[0009] In certain embodiments, the method for treating pulmonary arterial hypertension utilizes a drug delivery system designed for pulmonary drug delivery, including inhalation, for rapid delivery and onset of action of the active agent delivered to the target tissue utilizing the pulmonary arterial circulation. In this manner, the active agent can reach its target site in a therapeutically effective manner. In one embodiment, the method for treating PAH and / or idiopathic pulmonary disease is by the present composition using an oral inhalation device that can deliver the active agent deep into the alveoli of the lungs.
[0010] In one embodiment, the method comprises administering a stable pharmaceutical composition comprising one or more active agents comprising vasodilators comprising sildenafil, tadalafil, vardenafil, prostaglandins or analogs thereof, such as treprostinil or pharma- ceutically acceptable salts thereof, including treprostinil sodium, to treat PAH and deliver treprostinil to the systemic circulation of the subject's lungs by pulmonary inhalation using a dry powder inhaler. In one embodiment, the method comprises providing a patient in need of treatment with a dry powder inhaler comprising treprostinil in a stable dry powder formulation, and administering the active agent by oral inhalation.
[0011] In one embodiment, the drug delivery system comprises a dry powder inhaler containing a small molecule, e.g., a prostaglandin or analogue thereof, including treprostinil, and / or a diketopiperazine-based drug formulation for delivering a protein-based product for treating PAH. The method offers advantages over typical drug delivery methods such as oral tablets and subcutaneous and intravenous injection / infusion drug products that are sensitive to degradation and / or enzymatic deactivation.
[0012] In certain embodiments disclosed herein, a method of providing a prostaglandin formulation to a patient in need thereof is disclosed, the method comprising: selecting a patient to be treated for PAH; administering to the patient a dry powder formulation comprising treprostinil, wherein the treprostinil is combined with a diketopiperazine, including (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine, to generate a pharmaceutical formulation or composition suitable for pulmonary inhalation; and delivering the treprostinil formulation or composition to the patient's lungs in one or more breaths per treatment session using a breath-powered dry powder inhaler. In this and other embodiments, the dry powder formulation can be provided multiple times per day as needed by the patient, and the composition is provided in a reconstitutable cartridge containing about 1 μg to about 200 μg of treprostinil, 10 μg to about 100 μg, about 100 μg to about 150 μg, about 150 μg to about 300 μg of treprostinil, derivatives thereof, analogs thereof, or combinations thereof in the dry powder formulation per dose.
[0013] In some embodiments, the dry powder formulation can contain about 10 μg to about 300 μg of treprostinil per therapeutic dose in a cartridge or capsule. In one embodiment, a cartridge for single use can contain about 10 μg to about 90 μg of treprostinil for at least one inhalation. In some embodiments, the dry powder formulation is delivered with at least one inhalation per use or dose. In this and other embodiments, the dry powder formulation is delivered to a patient in less than 10 seconds, or less than 8 seconds, or less than 6 seconds per inhalation or breath. In one embodiment, the pharmaceutical dry powder composition comprises microcrystalline particles of fumaryl diketopiperazine, the particles being about 59 μg. 2 / g ~ approx. 63m 2 / g and has a pore size in the range of about 23 nm to about 30 nm.
[0014] Also disclosed herein is a method of treating a disease or disorder of pulmonary arterial hypertension, the method comprising: selecting a patient being treated for functional class I, II or III pulmonary arterial hypertension, or a PAH patient exhibiting a condition treatable with an active agent comprising treprostinil, epoprostenol, bosentan, ambrisentan, macisentan, sildenafil, tadalafil, riociguat, and the like, or a combination thereof, and typically treated only by oral or injectable administration; replacing said therapy with an inhalation therapy comprising providing the patient with an inhaler comprising an active agent in a stable dry powder composition for treating the disease or disorder, the stable dry powder composition comprising an active agent and a diketopiperazine; and administering the stable dry powder composition to the patient by pulmonary inhalation, thereby treating the disease or condition.
[0015] In an exemplary embodiment, a formulation for treating pulmonary arterial hypertension comprises treprostinil in an amount of up to 200 μg per dose, e.g., 1 μg, 5 μg, 10 μg, 15 μg, 20 μg, 30 μg, 60 μg, 90 μg, 100 μg, 120 μg, 150 μg, 180 μg, or 200 μg, and one or more pharma- ceutically acceptable carriers and / or excipients are administered to a subject per dose. In this embodiment, the pharma- ceutically acceptable carrier and / or additive can be formulated for oral inhalation to form particles, such as diketopiperazines, including fumaryl diketopiperazines; sugars, such as mannitol, xylitol, sorbitol, and trehalose; amino acids, including glycine, leucine, isoleucine, and methionine; surfactants, including polysorbate 80; cationic salts, including monovalent, divalent, and trivalent salts, including sodium chloride, potassium chloride, magnesium chloride, and zinc chloride; buffers, such as citrate and tartrate, or combinations of one or more carriers and / or additives. In certain embodiments, the formulation comprises a dry powder comprising treprostinil, a sugar, an amino acid, and a cationic salt, wherein the sugar is mannitol or trehalose, and the amino acid is leucine or isoleucine. In certain embodiments, the formulation can further comprise sodium chloride, potassium chloride, magnesium chloride, or zinc chloride, sodium citrate, sodium tartrate, or a combination thereof.
[0016] In an exemplary embodiment, the treprostinil dose is administered by one or more inhalations from a dry powder inhaler using a dry powder inhaler for oral inhalation. In this embodiment, a treprostinil inhalation powder dose is provided to a patient suffering from pulmonary arterial hypertension and in need of treatment, the dry powder inhaler comprises a container containing a cartridge, the container or cartridge contains a dry powder containing treprostinil and (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine, administered multiple times daily for six months, and the treprostinil is administered by oral inhalation early in the course of the disease as a first-line monotherapy for patients with functional class I, II or III. In this and other embodiments, the treprostinil composition comprises a single-dose capsule or cartridge containing 8 μg, 16 μg, 32 μg, 64 μg, 80 μg, or a combination of cartridges containing treprostinil or a salt thereof, which can be conveniently provided to the patient in a blister package. In some embodiments, the method of treating diseases including, but not limited to, PAH, interstitial lung disease (ILD), and / or pulmonary fibrosis comprises administering to a patient in need of treatment one or more capsules or cartridges to achieve the dose required for the individual patient. In some embodiments, the method comprises administering to the patient a predetermined dose of inhalable dry powder comprising treprostinil one or more times per day using a dry powder inhaler, as determined by a physician. In particular, the treatment regimen can be administered twice daily. In some embodiments, the method comprises administering a predetermined dose of inhalable dry powder per cartridge using a single inhalation per cartridge dose.
[0017] In one embodiment, a method for treating pulmonary arterial hypertension is provided, the method comprising providing to a patient in need of treatment a monotherapy using an inhalable dry powder comprising treprostinil and a pharma- ceutically acceptable carrier, and / or excipient, providing by oral inhalation using a dry powder inhaler and a dry powder container comprising the inhalable dry powder, and administering the dry powder formulation to the patient. In some embodiments, the treprostinil formulation comprises fumaryl diketopiperazine particles.
[0018] In one embodiment, a method for treating pulmonary arterial hypertension is provided comprising providing to a patient in need of treatment a combination therapy using an inhalable dry powder comprising treprostinil and fumaryl diketopiperazine, and administering separately in combination with an orally administered drug selected from a prostacyclin analogue, an endothelin receptor antagonist (ERA) including bocentran, ambricentran or macitentan, a soluble guanine cyclase agonist / stimulator such as riociguat, and a PDE-5 inhibitor including sildenafil, vardenafil, or tadalafil.
[0019] In another embodiment, the dry powder containing treprostinil and fumaryl diketopiperazine can be administered as part of a pre-combination therapy with an oral agent. In an alternative embodiment, an inhalable treprostinil composition containing a dose of fumaryl diketopiperazine and treprostinil powder, with the amount of treprostinil being about 1 μg to about 200 μg, can be administered in combination with an oral agent such as a PDE-5 inhibitor, or an endothelin receptor antagonist and / or combination therapy can be administered in place of a continuous parenteral infusion of a prostacyclin analogue in patients with severe disease and WHO functional class IV. Phosphodiesterase inhibitors, including PDE-5 inhibitors, can be formulated for inhalation alone or in combination with treprostinil, or if administered alone, can be administered subsequently as a combination therapy.
[0020] In another embodiment, the inhalation system includes a breath-powered dry powder inhaler, a container or cartridge containing a dry powder for delivery of an active agent, including a drug, to the pulmonary tract and lungs, the drug can include an inhalable drug formulation for pulmonary delivery, such as, for example, a composition comprising an active agent including a diketopiperazine, in a crystalline powder form that self-assembles in suspension, an amorphous powder form, and / or a microcrystalline powder form that includes crystals that do not self-assemble in suspension, or a combination thereof, and treprostinil, sildenafil, vardenafil, tadalafil, or a combination thereof. The cartridge or capsule can be assembled into a blister package for easy access to the treatment.
[0021] In alternative embodiments, the dry powder for inhalation may be formulated with other carriers and / or excipients besides the diketopiperazine, such as sugars including trehalose, buffers including sodium citrate, salts including sodium chloride and zinc chloride, and one or more active agents including treprostinil, vardenafil, and sildenafil.
[0022] In embodiments herein, a method of treating PAH includes administering a dry powder formulation comprising treprostinil and a pharma- ceutically acceptable carrier and / or excipient at a maximum amount of 200 μg of treprostinil to a patient with moderate to severe PAH using a dry powder inhaler comprising a movable member for loading a container comprising a pharmaceutical composition, the movable member being capable of configuring the container from a container-loading configuration to a dispensing configuration such that the inhaler creates an airflow through the inhaler during an inhalation maneuver, causing the contents of the container to enter the airflow path, and such that more than 60% of the dry powder dose in the container is delivered to the lungs in a single inhalation.
[0023] In some embodiments, the treatment regimen with inhaled dry powder varies depending on the patient's needs and can be one inhalation instead of each nebulization session as in standard treatment, which includes at least 1-4 inhalations per day depending on the severity of the disease.
[0024] In one embodiment, a kit for providing the composition to a patient undergoing treatment for PAH / ILD disease is also disclosed, which includes an inhaler, blisters containing various doses of the treprostinil composition, and instructions for use. In one embodiment, the kit can include a single blister type containing a dose or a combination of blisters with various dose contents depending on the patient's needs and treatment requirements. [Brief description of the drawings]
[0025] [Figure 1] Figure 1 shows a graph of data comparison regarding the relationship between treprostinil AUC0-5 (area under the curve) and increasing dose administered to patients in a study receiving treprostinil inhalation powder (TIP=TreT) administered by dry powder inhaler and with standard of care using TYVASO® administered by nebulization. As can be seen from the graph, both data sets show that administration of doses by either method is proportional to increasing amounts of treprostinil. [Diagram 2] FIG. 2 shows a graph comparing data regarding the relationship between treprostinil Cmax (maximum blood concentration) and increasing dose administered to patients in a study receiving treprostinil inhalation powder (TIP=TreT) administered by dry powder inhaler and with standard treatment with TYVASO® administered by nebulization. [Diagram 3] FIG. 3 shows a graph of the change from baseline in the 6MWD test for subjects treated with the present treprostinil inhalation powder (TIP), demonstrating an overall significant improvement (increase of 8 meters; p=0.0217) at week 3 of treatment and throughout the 59 weeks of the study. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] In the embodiments disclosed herein, a dry powder inhaler is described, which comprises a dry powder composition and a container or cartridge for delivering the dry powder containing a medicament to a subject by oral inhalation.In one embodiment, the dry powder inhaler is a breath-powered dry powder inhaler, and the container or cartridge is designed to contain an inhalable dry powder, which includes, but is not limited to, an active ingredient, which includes a pharmacologic active substance, and optionally a pharmacologic acceptable carrier.In particular, the dry powder inhaler is for treating pulmonary arterial hypertension.
[0027] Dry powder inhalers are provided in various embodiments of shapes and sizes, are reusable, easy to use, inexpensive to manufacture, and / or can be manufactured in large quantities in simple steps using plastic or other acceptable materials. Various embodiments of dry powder inhalers are provided herein, and generally, the inhalation system includes an inhaler, a cartridge filled with powder, and an empty cartridge. The inhalation system of the present invention can be designed to be used with any type of dry powder. In one embodiment, the dry powder is a relatively highly cohesive powder that requires optimal deagglomeration conditions. In one embodiment, the inhalation system provides a small, reusable, breath-powered inhaler in combination with a single-use cartridge containing a pre-metered dose of the dry powder formulation. The inhaler can deliver a dry powder dose in one inhalation to a patient in less than 10 seconds in the treatment of pulmonary arterial hypertension. In certain embodiments, oral inhalation can deliver more than 60% of the powder dose in less than 6 seconds, less than 4 seconds, and less than 2 seconds.
[0028] As used herein, the term "unit dose inhaler" refers to an inhaler that is adapted to receive a single enclosure, cartridge, or container containing a dry powder formulation and delivers a single dose of the dry powder formulation from the single container to a user via inhalation. It should be understood that in some cases, multiple unit doses are required to provide a particular dosage to the user.
[0029] As used herein, a "cartridge" is a housing configured to hold or contain a dry powder formulation, and is a powder-containing housing with a cup or container and a lid. The cartridge is made of a rigid material, and the cup or container is movable in a translational motion relative to the lid, or vice versa.
[0030] As used herein, "powder agglomerate" refers to a conglomerate or aggregate of powder particles having irregular geometric shapes such as width, diameter, and length.
[0031] As used herein, "unit dose" refers to a dry powder formulation that is pre-metered for inhalation. Alternatively, a unit dose may be a single housing that includes a container with a single or multiple doses of the formulation that can be delivered by inhalation as a single metered amount. A unit dose housing / cartridge / container contains a single dose. Alternatively, it may comprise multiple individually accessible compartments, each containing a unit dose.
[0032] As used herein, the term "about" is used to indicate a value that includes the standard deviation of error for the device or method being employed to determine the value.
[0033] The term "fine particles" as used herein refers to particles having a diameter of about 0.5 to about 1000 μm, regardless of the exact external or internal structure. Fine particles having a diameter between about 0.5 and about 10 microns can successfully pass through most of the natural barriers to reach the lungs. A diameter of less than about 10 microns is required to pass through the turn of the throat, and a diameter of about 0.5 μm or more is required to prevent exhalation. To reach the deep lungs (or alveolar region) where most efficient absorption is believed to occur, it is preferable to maximize the proportion of particles contained in the "respirable fraction" (RF), and generally these particles having an aerodynamic diameter of about 0.5 to about 6 μm are accepted, although some literature uses somewhat different ranges, measured using standard techniques such as, for example, the Anderson Cascade Impactor. Other impactors, such as the NEXT GENERATION IMPACTOR® (NGI®, MSP Corporation), can be used to measure aerodynamic particle size, for which respirable fraction is defined at similar aerodynamic sizes, e.g., less than 6.4 μm. In some embodiments, a laser diffraction device is used to determine particle size, e.g., as disclosed in U.S. Pat. No. 8,508,732, the disclosure of which is incorporated herein in its entirety for its relevant teachings regarding laser diffraction, and the volume median geometric diameter (VMGD) of the particles is measured to evaluate the performance of the inhalation system. For example, in various embodiments, cartridge emptiness of 80% or more, 85% or more, or 90% or more and VMGD of emitted particles less than 12.5 μm, less than 7.0 μm, or less than 4.8 μm can indicate progressively better aerodynamic performance.
[0034] Respirable fraction at fill (RF / fill) represents the percentage (%) of powder in a dose that is respirable when released from an inhaler upon release of the powder contents loaded for use as a dose, i.e., the percentage of particles released from a loaded dose that are suitable for lung delivery, and is an indicator of the aerodynamic performance of the particulate. As described herein, an RF / fill value of 40% or greater reflects acceptable aerodynamic performance characteristics. In certain embodiments disclosed herein, the respirable fraction at fill may be greater than 50%. In an exemplary embodiment, the respirable fraction at fill is up to about 80%, with about 80% of the fill being released with a particle size of less than 5.8 μm, as measured using standard techniques.
[0035] As used herein, the term "dry powder" refers to a particulate composition that is not suspended or dissolved in a propellant or other liquid. It does not necessarily mean that it is completely free of all water molecules.
[0036] "Amorphous powder," as used herein, includes all non-crystalline powders and refers to dry powders lacking any distinct repeating form, shape, or structure.
[0037] The present disclosure also provides improved powders, compositions, methods of making particles, and therapeutic methods that allow for improved delivery of drugs to the lungs to treat diseases and disorders in subjects. The embodiments disclosed herein achieve improved delivery by providing crystalline diketopiperazine compositions that include microcrystalline diketopiperazine particles with high drug adsorption capacity to obtain powders with high drug loading of one or more active agents. Powders made with the microcrystalline particles of the present invention can deliver increased drug loading with a smaller powder dosage, facilitating drug delivery to patients. Depending on the starting material, the powders can be made by a variety of methods, including methods that utilize surfactant-free or surfactant-containing solutions.
[0038] In alternative embodiments disclosed herein, the drug delivery system can include a dry powder for inhalation comprising a multiplicity of substantially uniform microcrystalline particles, the microcrystalline particles can have a substantially hollow spherical structure and can include a shell that can be porous and includes crystals of diketopiperazine that do not self-assemble in suspension or solution. In certain embodiments, the microcrystalline particles can be substantially solid particles that are substantially hollow spherical and include crystals of diketopiperazine, depending on the drug and / or drug content provided, and other factors in the method of manufacture of the powder. In one embodiment, the microcrystalline particles have a diameter of about 0.43 cm as determined by BJH adsorption. 3 / g, approx. 0.4cm 3 / g ~ approx. 0.45cm 3 The particles include relatively porous particles having an average pore volume in the range of about 23 nm to about 30 nm, or about 23.8 nm to about 26.2 nm.
[0039] Certain embodiments disclosed herein include a dry powder comprising a multiplicity of substantially uniform microcrystalline particles, the particles having a substantially spherical structure including a shell that may be porous, the particles comprising crystals of diketopiperazine that do not self-assemble in suspension or solution, having a volume median geometric diameter of less than 5 μm, or less than 2.5 μm, and comprising an active agent.
[0040] In certain embodiments herein, up to about 92% of the microcrystalline particles have a volume median geometric diameter of 5.8 μm. In one embodiment, the shell of the particle is constructed of intertwining diketopiperazine microcrystals with one or more drugs adsorbed on their surface. In some embodiments, the particle can entrap a drug in its internal void volume and / or a combination of a drug adsorbed on the surface of the crystal and a drug entrapped in the internal void volume of the sphere.
[0041] In one embodiment, a diketopiperazine composition is provided that includes a multiplicity of substantially uniformly formed microcrystalline particles, the particles having a substantially hollow spherical structure and including a shell containing crystals of non-self-assembled diketopiperazine, the particles being formed by a method that includes combining a diketopiperazine having a trans isomer content in the range of about 45%-65% in solution and an acetic acid solution without the presence of a surfactant, simultaneously homogenizing the diketopiperazine in a high shear mixer at a high pressure of up to 2,000 psi to form a precipitate, washing the precipitate in suspension with deionized water, concentrating the suspension, and drying the suspension in a spray drying apparatus. The microcrystalline particles can be preformed without subsequent use or can be combined with an active agent in suspension prior to spray drying.
[0042] The method may further include the step of adding a solution containing an active agent or ingredient, such as a drug or bioactive agent, in admixture with other pharma- ceutically acceptable carriers and / or excipients prior to the spray drying step, such that the active agent or ingredient is adsorbed and / or entrapped on or within the particles. The particles produced by this method may be in the submicron size range prior to spray drying.
[0043] In one embodiment, a diketopiperazine composition is provided comprising a multiplicity of substantially uniformly formed microcrystalline particles, the particles having a substantially hollow spherical structure and including a shell comprising non-self-assembled crystals of diketopiperazine, the particles having a volume average geometric diameter of 5 μm or less, the particles being formed by a process comprising combining diketopiperazine in solution and an acetic acid solution in the absence of a surfactant and simultaneously homogenizing the mixture in a high shear mixer at a high pressure of up to 2,000 psi to form a precipitate, washing the precipitate in suspension with deionized water, concentrating the suspension, and drying the suspension in a spray dryer.
[0044] The method may further include the step of adding, with mixing, a solution containing an active agent or ingredient, such as a drug or bioactive agent, prior to the spray drying step, such that the active agent or ingredient is adsorbed and / or entrapped on or within the particles. The particles produced by this method may be in the submicron size range prior to spray drying.
[0045] In one embodiment, a diketopiperazine composition is provided comprising a multiplicity of substantially uniformly formed microcrystalline particles, the microcrystalline particles having a substantially hollow spherical structure and including a shell comprising non-self-assembled crystals of diketopiperazine, the particles having a volume mean geometric diameter of 5 μm or less, the particles being formed by a process comprising combining diketopiperazine in solution and an acetic acid solution, in the absence of a surfactant or an activator, simultaneously homogenizing in a high shear mixer at a high pressure of up to 2,000 psi to form a precipitate, washing the precipitate in suspension with deionized water, concentrating the suspension, and drying the suspension in a spray dryer.
[0046] In some embodiments, where the starting material containing the active ingredient is a highly viscous extract or a material with a viscous appearance like honey, the microcrystalline particles are formed by washing in water using tangential flow filtration as described above before combining with the extract or viscous material. After washing in water, the resulting particle suspension is freeze-dried to remove water and resuspended in an alcoholic solution containing ethanol or methanol before adding the active ingredient as a solid or in suspension or solution. In one embodiment, optionally, the method of making the composition includes adding optional additional additives including one or more amino acids such as leucine, isoleucine, norleucine, methionine, or one or more phospholipids, such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), simultaneously with the active ingredient or subsequent to the addition of the active ingredient and before spray drying. In certain embodiments, forming the composition includes preparing the extract containing the desired active agent, optionally by filtering or freezing, to separate and remove layers of unwanted materials, such as lipids, to increase its solubility.
[0047] The method may further include adding a solution to the mixture with mixing prior to the spray drying step, the mixing may be performed with or without homogenization in a high shear mixer, such that the active agent or ingredient is adsorbed and / or entrapped within or on the particle surface, the solution comprising an active agent or ingredient, such as a drug or bioactive agent. The particles produced by this method may be in the submicron size range prior to spray drying, or the particles may be formed from the solution during spray drying.
[0048] In some embodiments herein, the drug content can be delivered with crystalline powder using FDKP and freeze-dried or spray-dried to a content of about 10%, or about 20%, or about 30% or more. In embodiments using microcrystalline particles formed from FDKP or FDKP disodium salt that are not self-assembled and include submicron-sized particles, the drug content can typically be greater than 0.01% (w / w). In one embodiment, the drug content delivered with the microcrystalline particles is about 0.01% (w / w) to about 75% (w / w), about 1% to about 50% (w / w), about 10% (w / w) to about 25% (w / w), or about 10% to about 20% (w / w), or from 5% to about 30%, or greater than 25%, depending on the drug being delivered. In an exemplary embodiment where the drug is a peptide such as insulin, the microparticles of the invention typically contain approximately 10% to 45% (w / w), or about 10% to about 20% (w / w) insulin. In certain embodiments, the drug content of the particles can vary depending on the form and size of the drug to be delivered.
[0049] In an exemplary embodiment, the composition comprises a dry powder comprising microcrystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine, and treprostinil is adsorbed to the particles, and the content of treprostinil in the composition comprises a range of up to about 20% (w / w), about 0.5% to about 10% (w / w), or about 1% to about 5% of the dry powder. In one embodiment, the composition herein may comprise other additives suitable for inhalation, such as amino acids including methionine, isoleucine, and leucine. In this embodiment, the treprostinil composition may be used for the prevention and treatment of pulmonary hypertension by self-administering an effective dose comprising about 1 mg to 15 mg of a dry powder composition comprising microcrystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine and treprostinil in a single inhalation. In certain embodiments, the treprostinil content in the formulation can be from about 1 μg to about 200 μg. In one embodiment, the dry powder content of a cartridge containing treprostinil can be 20 μg, 30 μg, 60 μg, 90 μg, 120 μg, 150 μg, 180 μg, or 200 μg. In other embodiments, the dry powder content of a cartridge containing treprostinil can be about 20 μg, about 30 μg, about 60 μg, about 90 μg, about 120 μg, about 150 μg, about 180 μg, or about 200 μg, between about 20 μg to about 60 μg, about 50 μg to about 90 μg, about 60 μg to about 120 μg, about 90 μg to about 120 μg, about 100 μg to about 150 μg, about 120 μg to about 150 μg, about 120 μg to about 180 μg, about 150 μg to 180 μg, or about 180 μg to 200 μg.
[0050] In an alternative embodiment, the pharma- ceutically acceptable carrier for producing dry powders can include any carrier or additive that is useful for producing dry powders and suitable for pulmonary delivery. Examples of pharma- ceutically suitable carriers and additives include sugars, including monosaccharides and polysaccharides such as lactose, mannose, sucrose, mannitol, trehalose, etc.; amino acids, such as citrate, glycine, L-leucine, isoleucine, trileucine, etc.; tartrate, methionine, vitamin A, vitamin E, zinc citrate, sodium citrate, trisodium citrate, sodium tartrate, sodium chloride, zinc chloride, zinc tartrate, polyvinylpyrrolidone, polysorbate 80, phospholipids, including diphosphotidylcholine, etc.
[0051] In one embodiment, there is also provided a method of self-administering a dry powder formulation into one's lungs using a dry powder inhalation system, the method including obtaining a dry powder inhaler having a mouthpiece in a closed position, obtaining a cartridge containing a pre-metered dose of the dry powder formulation in a storage structure, opening the dry powder inhaler and attaching the cartridge, closing the inhaler and moving the cartridge into a dosing position, placing the mouthpiece over one's mouth, and taking a single deep inhalation to deliver the dry powder formulation.
[0052] In yet another embodiment, a method for treating obesity, hyperglycemia, insulin resistance, pulmonary hypertension, anaphylaxis, and / or diabetes is disclosed. The method includes, for example, administering an inhalable dry powder composition or formulation comprising a diketopiperazine having the formula (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine. In this embodiment, the dry powder composition can include a diketopiperazine salt. In yet another embodiment, a dry powder composition or formulation is provided in which the diketopiperazine is (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine, with or without a pharma- ceutically acceptable carrier or excipient.
[0053] An inhalation system for delivering a dry powder formulation to the lungs of a patient is provided, the system including a dry powder inhaler configured with a flow path having a total resistance to flow in a dosing configuration in the range of 0.065 to about 0.200 (√kPa) per liter per minute. The dry powder inhaler can be provided with a dry powder formulation for single use that can be disposed of after use, or with replaceable individual doses of the dry powder formulation within a multi-use inhaler, where the individual dose housings or containers can be disposed of after use.
[0054] In one embodiment, a dry powder inhalation kit is provided that includes the dry powder inhaler described above and one or more drug cartridges containing a dry powder formulation for treating disorders or diseases such as airway and lung diseases, including pulmonary arterial hypertension, cystic fibrosis, respiratory infections, cancer, and other systemic diseases, including endocrine disorders including diabetes and obesity.
[0055] Also provided is a method of treating a disease or disorder in a patient using an embodiment of the dry powder inhaler disclosed herein. The method of treatment includes providing a patient in need of treatment with a dry powder inhaler including a cartridge containing a dose of an inhalable formulation including an active ingredient selected from the group described above, and a pharma- ceutically acceptable carrier and / or excipient, and having the patient inhale deeply through the dry powder inhaler for about 3-4 seconds to deliver the dose. In this manner, the patient can then resume normal breathing patterns. In all embodiments disclosed herein, the patient can then resume normal breathing patterns.
[0056] A method for preparing a pharmaceutical composition comprising treprostinil is disclosed. The method includes preparing a dry powder composition for oral inhalation comprising treprostinil in an amount of 0.25% (w / w) to about 10% (w / w), or about 1% (w / w) to about 5% (w / w) in the composition, and microcrystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine. In one embodiment, the method includes preparing a suspension of a dry powder composition containing crystalline particles of diketopiperazine, including (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine, and an acetic acid solution at a temperature ranging from 13° C. to about 20° C. while mixing the suspension in a high shear mixer, washing the suspension with deionized water to remove acetic acid, pelletizing the suspension in a freeze granulator, and drying the suspension in a freeze dryer to recover crystalline particles of diketopiperazine, and each step may be discontinuous. In this embodiment, the dry powder pellets may be stored at room temperature or refrigerated until use. In another embodiment, the method may be continuous.
[0057] In one embodiment, the method includes resuspending a dry powder containing dry microcrystalline particles of diketopiperazine in a solution of deionized water and alcohol to a suspension containing about 0.5% to about 2% solids, or about 1% to about 4% solids, or about 1% to about 10% solids, or more than 10%, preparing a solution containing treprostinil in dilute aqueous ethanol or absolute ethanol, mixing the solution containing treprostinil with the crystalline particles of diketopiperazine in the suspension, and spray drying the suspension to form a dry powder composition. In one embodiment, the method includes adding more ethanol to the suspension to achieve an ethanol / water density close to that of treprostinil, which reduces the buoyancy of treprostinil and disperses it more uniformly in the suspension. In another embodiment, the method includes adding treprostinil in dry powder form to a suspension containing diketopiperazine particles with mixing until the powder dissolves, and spray drying or freeze drying the suspension. In one embodiment, the method comprises dissolving treprostinil, a derivative or an analog thereof in an ethanol solution prior to adding the solution to the diketopiperazine suspension.
[0058] In another embodiment, a method for producing an inhalable dry powder composition for treating pulmonary disease includes preparing a solution containing up to about 30% by weight, or up to 40% by weight, of diketopiperazine in aqueous ammonium solution, filtering the formed solution, combining the solution with filtered aqueous acetic acid in a high shear mixer while mixing to form a precipitate, concentrating the suspension by washing in multiple steps with deionized water, determining the percent solids in the suspension, and lyophilizing or spray drying the suspension to form a bulk FDKP microcrystalline powder. In an exemplary embodiment, the dry powder containing FDKP is resuspended in purified deionized water with or without ethanol, and the pH of the suspension is adjusted to about 4.5, or about 5.0. A solution of an active ingredient, such as treprostinil, is prepared, for example, by dissolving the active ingredient in a solution containing 70% to about 99.5% ethanol, or 70% to about 99.5% absolute ethanol. The solution containing the active ingredient is added to a particle suspension containing FDKP while mixing, and the solution is subsequently spray-dried in a spray-drying apparatus.
[0059] The following examples provide some methods for producing dry powders suitable for use in the inhalers described herein, and data obtained from experiments using the dry powders.
[0060] (Example) Example 1 Preparation of surfactant-free dry powder containing FDKP microcrystalline powder for use in inhalers In an exemplary embodiment, a surfactant-free dry powder containing FDKP microcrystalline particles was prepared. Approximately equal masses of acetic acid solution (Table 1) and FDKP solution (Table 2), held at approximately 25° C.±5° C., were mixed in a dual-feed high shear mixer at 0.001-in. 2The suspension was fed at 2000 psi through an opening in the nozzle to form a precipitate by homogenization. The precipitate was collected in deionized (DI) water at approximately the same temperature. The weight percent content of FDKP microcrystals in the suspension is approximately 2-3.5%. The concentration of FDKP in the suspension can be analyzed for solids by oven drying method. The FDKP microcrystal suspension can be optionally washed by tangential flow filtration using deionized water. The FDKP microcrystals can be optionally isolated by filtration, centrifugation, spray drying or freeze drying. The dried powder can be stored refrigerated or at room temperature and / or used to add active ingredients.
[0061] [Table 1]
[0062] [Table 2]
[0063] Dry powders (A, B, C and D) containing microcrystalline particles produced by the method described above were tested for various properties including surface area, moisture content and porosity measurements. Four different powders were used in this experiment. All powders tested had a residual moisture content of 0.4%. Table 2a shows the data obtained from this study.
[0064] [Table 2a]
[0065] The data in Table 2a show that the surface area of the spray-dried bulk dry powder containing microcrystalline particles of the tested sample is 59 m 2 / g~63m 2 Porosity data indicates that the microcrystalline particles are in the range of about 0.43 cm3 / g as measured by BJH adsorption. 3Porosimetry data indicates that these particles are relatively porous with an average pore volume of about 0.36 cm / g and an average pore size ranging from about 23.8 nm to 26.2 nm. 3 This shows that this is different from the FDKP microparticles of the prior art, which have been shown to have an average pore volume of 1 / g and an average pore diameter of about 20 nm to about 22.6 nm.
[0066] Example 2 Preparation of dry powder containing microcrystalline FDKP particles containing treprostinil A solution containing 0.2-1.0 wt% treprostinil in ethyl alcohol was added to the suspension of FDKP microcrystals obtained as described in Example 1. The mixture was spray-dried using a Buchi B290 spray dryer equipped with a high-efficiency cyclone. Nitrogen (60 mm) was used as the process gas. The mixture was dried using 10-12% pump capacity, 90-100% suction rate, and an inlet temperature of 170-190°C. The wt% concentration of treprostinil in the resulting powder was 0.5-10%. The delivery efficiency of these powders after release from the dry powder inhaler ranged approximately from 50% to 70%.
[0067] Example 3 Use of Treprostinil-Fumaryl Diketopiperazine (TIP) Compositions in Healthy Subjects The study was an open-label, single ascending dose study in 36 healthy normal volunteers who were sequentially assigned to six cohorts receiving a single dose of TIP (30, 60, 90, 120, 150, and 180 μg). Safety and tolerability of the dry powder composition containing treprostinil was evaluated in each successive cohort before dose escalation for the next cohort using a dry powder inhaler system containing a cartridge dose in a single inhalation. Blood samples were collected prior to and at selected times throughout 480 min after administration of the composition. Blood samples were analyzed for treprostinil using validated analytical methods, and PK parameters were calculated using noncompartmental methods.
[0068] A total of 36 subjects were randomized. There were no serious adverse events, serious adverse events, or deaths during the study. No adverse events led to early subject termination. The most frequently reported adverse events were cough (n=11, 30.6%) and headache (n=8, 22%). Bioanalytical data confirmed that plasma concentrations of treprostinil and exposure to treprostinil achieved clinically relevant concentrations comparable to those observed in previous TYVASO® single-dose clinical studies (Table 3, Figures 1 and 2). Table 3 shows the study design of dosing comparing a single inhalation of TYVASO® versus a TIP cartridge with a DPI. Figure 1 shows the AUC0-5 and doses for subjects treated with TIP and TYVASO®. Figure 2 shows the Cmax (ng / mL) of various amounts of treprostinil administered as described in Table 3 for TIP and TYVASO®. The data in Figures 1 and 2 show that the Cmax and AUC of treprostinil increased linearly with increasing dose. The results are also shown in Table 4.
[0069] [Table 3]
[0070] [Table 4]
[0071] The PK study data demonstrates that AUC0-5 was generally comparable for each TIP-DPI and TYVASO® dose level. The data also show that across dose comparisons, TIP-DPI Cmax values were slightly higher than TYVASO® Cmax values. The above data demonstrate that TIP-DPI is more efficient at delivering treprostinil to an individual in a single inhalation than the nebulized form of TYVASO®, which requires multiple inhalations per session, and that the DPI form requires less treprostinil per inhalation.
[0072] The adverse event profile is consistent with known prostacyclin effects and previous studies of TYVASO®. Intersubject variability for both AUC0-5 and Cmax was approximately half for TIP-DPI compared to TYVASO®. AUC0-5 and Cmax for TIP-DPI and TYVASO® increased approximately dose-proportionally, with median Tmax of approximately 10 minutes for TIP-DPI and 10-15 minutes for TYVASO®.
[0073] Example 4 Use of Treprostinil-Fumaryl Diketopiperazine Inhalation Powder (TIP) in Subjects With Pulmonary Arterial Hypertension (PAH) Treated With Treprostinil Nebulization (TYVASO®) The study design was a comparative study to evaluate the safety and tolerability of TIP in patients with PAH. The study also evaluated the systemic exposure and pharmacokinetics (PK) of treprostinil in 51 patients with PAH (WHO functional class I (11.8%), II (60.8%), and III (27.5%), age range 23-82 years). The study included 43 women and 8 men. Treprostinil was delivered by nebulization (TYVASO®) or dry powder inhaler (TIP). TIP was delivered by DPI (DREAMBOAT® inhaler, Mankind Subjects were administered a single inhalation per cartridge dose using a treprostinil sedation system (Corporation). Subjects (51) received 32 μg, 48 μg, and 64 μg of treprostinil twice daily for three weeks, with 49 subjects continuing treatment. Serial pharmacokinetic sampling was taken at baseline and three weeks after study initiation, and treatment was continued twice daily for the remainder of the study. Follow-up clinic visits occurred every eight weeks after study initiation (see Table 5 below).
[0074] [Table 5]
[0075] Baseline subject physical characteristics, as assessed by the 6-minute walking distance test (6MWD) in patients using nebulized treprostinil, were measured before the treatment period, and also at various intervals and at the end of the study. Figure 3 shows the results of the study treatment. As can be seen, the change from baseline in the TIP-wide 6MWD test shows a significant improvement at week 3 of treatment (8.0 m increase; p=0.0217). The improvement in TIP-wide 6MWD was sustained in subjects treated for 59 weeks. Patients (95.7%) reported overall satisfaction with the TIP-DPI when compared to the treprostinil nebulizer.
[0076] At weeks 3 and 11, patients were administered the PAH-SYMPACT, a well-validated patient-reported outcome questionnaire, to assess PAH symptoms and impact. The PAH-SYMPACT contains four domains (cardiopulmonary symptoms, cardiovascular symptoms, physical impact, and cognitive / emotional impact) and was administered at baseline, week 3, and week 11 of the study. Data revealed a trend toward improvement at both weeks 3 and 11 in subjects receiving TIP-DPI. Mean changes from baseline were lower in all PAH-SYMPACT domain scores at both weeks (range: -0.05 to -0.22), with significant improvements in physical impact scores (range: -1.1 to 1.0; p = 0.0438) and cognitive / emotional impact (range: -1.3 to 0.5; p = 0.0048) at week 3.
[0077] The study report also showed a reduction in adverse events during the treatment phase in patients treated with TIP compared to standard of care with TYVASO® throughout the study (see Tables 6 and 7).
[0078] [Table 6]
[0079] [Table 7]
[0080] Overall, TreT / treprostinil was safe and well tolerated and produced clinically relevant concentrations of treprostinil when inhaled as a dry powder.
[0081] The foregoing disclosure is an exemplary embodiment. It should be appreciated by those skilled in the art that the devices, techniques, and methods disclosed herein set forth representative embodiments that work well in the practice of the present disclosure. However, those skilled in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments disclosed with like or similar results without departing from the spirit and scope of the invention.
[0082] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weights, reaction conditions, and the like used in the specification and claims should be understood in all instances to be modified by the term "about". Accordingly, unless otherwise indicated, the numerical parameters set forth in the following specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained. At the very least, and without limiting the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed by applying ordinary rounding techniques in light of at least the number of reported significant digits. Notwithstanding that the numerical ranges and parameters setting forth broad ranges are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. However, any numerical value inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0083] The terms "a", "an", "the", and similar referents used in the context of describing the present invention (particularly in the context of the claims below) should be construed to encompass both the singular and the plural, unless otherwise specified herein or clearly contradicted by context. The recitation of ranges of values herein is merely intended to serve as a shorthand method of individually referring to each individual value falling within the range. Unless otherwise indicated herein, each individual value is incorporated herein as if it were individually set forth herein. All methods described herein can be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is merely for the purpose of better understanding the present invention and is not intended to impose limitations on the scope of the invention as claimed. No language in this specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0084] Use of the term "or" in the claims is used to mean "and / or" unless expressly indicated to mean alternatives only or the alternatives are mutually exclusive, however, the present disclosure supports a definition that means alternatives only and "and / or."
[0085] Groupings of alternative elements or embodiments disclosed herein should not be construed as limitations. Each group member may be referenced and claimed individually or in any combination with other members of the group or other elements described herein. It is anticipated that one or more members of a group may be included in or deleted from a group for reasons of convenience and / or patentability. When such inclusion or deletion is made, the specification is deemed to include the modified group, thus satisfying the description of all Markush groups used in the appended claims.
[0086] Preferred embodiments are described herein, including the best mode for carrying out the invention known to the inventors. Of course, variations of these preferred embodiments will become apparent to those skilled in the art upon reading the foregoing description. The inventors expect those skilled in the art to adopt such variations as appropriate, and the inventors intend the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, the invention encompasses any combination of the above-described elements in all possible variations thereof unless otherwise indicated herein or clearly contradicted by context.
[0087] Certain embodiments disclosed herein may be further limited in the claims using the language consisting of or consisting essentially of. When used in the claims, whether as filed or added by amendment, the transitional term "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional term "consisting essentially of" limits the claim to certain materials or steps, and those that do not materially affect the basic and novel characteristic(s). The embodiments so claimed are essentially or explicitly described and enabled herein.
[0088] Additionally, throughout this specification, numerous references are made to patents and printed publications. Each of the above cited references and printed publications is individually incorporated herein by reference in its entirety.
[0089] Moreover, it should be understood that the embodiments disclosed herein are illustrative of the principles of the invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, and not of limitation, alternative configurations may be utilized in accordance with the teachings herein. Accordingly, the invention is not limited to that precisely as shown and described.
[0090] (Additional Note) (Appendix 1) 1. A method for treating pulmonary hypertension, comprising administering to a patient in need of treatment a pharmaceutical dry powder composition comprising treprostinil and one or more pharma- ceutically acceptable salts thereof at a dose of up to 200 μg, and a pharma- ceutically acceptable carrier and / or excipient.
[0091] (Appendix 2) 2. The method of claim 1, wherein the pharmaceutical dry powder composition is an inhalable dry powder comprising a diketopiperazine.
[0092] (Appendix 3) The method of claim 1, wherein the diketopiperazine is (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine.
[0093] (Appendix 4) 2. The method of claim 1, wherein the dose of treprostinil is about 10 μg to about 180 μg in the dry powder composition.
[0094] (Appendix 5) 2. The method of claim 1, wherein the pharmaceutical dry powder composition is in a substantially crystalline form.
[0095] (Appendix 6) 2. The method of claim 1, wherein the pharmaceutical dry powder composition is provided as a single cartridge containing 8 μg, 16 μg, 24 μg, 32 μg, 64 μg, or 80 μg of treprostinil.
[0096] (Appendix 7) 2. The method of claim 1, wherein the patient is administered one or more cartridges of the pharmaceutical dry powder composition per dose.
[0097] (Appendix 8) 2. The method of claim 1, wherein the pharmaceutical dry powder composition is administered in a single inhalation per cartridge, one or more times daily.
[0098] (Appendix 9) 2. The method of claim 1, wherein the patient is administered the dry powder formulation twice daily.
[0099] (Appendix 10) 1. A method of treating pulmonary arterial hypertension, comprising administering to a patient in need of treatment by oral inhalation using a dry powder inhaler containing an inhalable dry powder composition comprising up to 200 μg of treprostinil and crystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine.
[0100] (Appendix 11) 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the dry powder further comprises one or more pharma- ceutically acceptable carriers and / or excipients selected from the group consisting of lactose, mannose, sucrose, mannitol, trehalose, sodium citrate, trisodium citrate, zinc citrate, glycine, L-leucine, isoleucine, trileucine, sodium tartrate, zinc tartrate, methionine, vitamin A, vitamin E, sodium chloride, zinc chloride, polyvinylpyrrolidone, and polysorbate 80.
[0101] (Appendix 12) 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the one or more pharma- ceutically acceptable carriers and / or excipients are sodium citrate, sodium chloride, leucine or isoleucine, and trehalose.
[0102] (Appendix 13) 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the dry powder composition is provided in a single cartridge containing 8 μg, 16 μg, 24 μg, 32 μg, 64 μg, or 80 μg of treprostinil.
[0103] (Appendix 14) 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the dry powder composition is administered in a single inhalation from the dry powder inhaler in less than 10 seconds and the treprostinil reaches a T in the patient's blood in less than about 10 minutes.
[0104] (Appendix 15) 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the patient is administered the dry powder formulation twice a day.
[0105] (Appendix 16) 1. A method for producing an inhalable dry powder composition comprising the steps of: preparing a suspension of microcrystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine in aqueous ammonia and combining with an acetic acid solution in a high shear mixer at a temperature ranging from 13° C. to about 20° C. while mixing in the high shear mixer to form a suspension; washing the suspension with water, pelletizing the suspension in a freeze granulator, and drying the suspension in a freeze dryer to recover the microcrystalline particles of the diketopiperazine; resuspending the microcrystalline particles of the diketopiperazine in a solution of deionized water and ethanol, preparing a hydrophobic compound in about 70% to about 100% ethanol solution, adding the solution to the suspension with mixing, and drying the suspension; A method comprising:
[0106] (Appendix 17) 17. The method of claim 16, wherein the hydrophobic compound is treprostinil, a derivative thereof, or an analog thereof.
[0107] (Appendix 18) 17. The method of claim 16, wherein the resuspension step comprises drying crystalline particles of diketopiperazine in a solution of deionized water and alcohol, the solution containing about 0.2% to about 2% solids in the suspension, or about 1% to about 4% solids in the suspension, or about 1% to about 10% solids in the suspension.
Claims
1. 1. A method of treating pulmonary hypertension, comprising administering to a patient in need of treatment a pharmaceutical dry powder composition comprising treprostinil and one or more pharma- ceutically acceptable salts thereof at a dose of up to 200 μg, and a pharma- ceutically acceptable carrier and / or excipient.
2. 10. The method of claim 1, wherein the pharmaceutical dry powder composition is an inhalable dry powder comprising a diketopiperazine.
3. 2. The method of claim 1, wherein the diketopiperazine is (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine.
4. The method of claim 1, wherein the dose of treprostinil is from about 10 μg to about 180 μg in the dry powder composition.
5. 10. The method of claim 1, wherein the pharmaceutical dry powder composition is in a substantially crystalline form.
6. 10. The method of claim 1, wherein the pharmaceutical dry powder composition is provided as a single cartridge containing 8 μg, 16 μg, 24 μg, 32 μg, 64 μg, or 80 μg of treprostinil.
7. 10. The method of claim 1, wherein the patient is administered one or more cartridges of the pharmaceutical dry powder composition per dose.
8. 13. The method of claim 1, wherein the pharmaceutical dry powder composition is administered in a single inhalation per cartridge, one or more times daily.
9. 13. The method of claim 1, wherein the patient is administered the dry powder formulation twice daily.
10. 1. A method of treating pulmonary arterial hypertension comprising administering to a patient in need of treatment by oral inhalation using a dry powder inhaler containing an inhalable dry powder composition comprising up to 200 μg of treprostinil and crystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine.
11. 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the dry powder further comprises one or more pharma- ceutically acceptable carriers and / or additives selected from the group consisting of lactose, mannose, sucrose, mannitol, trehalose, sodium citrate, trisodium citrate, zinc citrate, glycine, L-leucine, isoleucine, trileucine, sodium tartrate, zinc tartrate, methionine, vitamin A, vitamin E, sodium chloride, zinc chloride, polyvinylpyrrolidone, and polysorbate 80.
12. 11. The method of claim 10, wherein the one or more pharma- ceutically acceptable carriers and / or excipients are sodium citrate, sodium chloride, leucine or isoleucine, and trehalose.
13. 11. The method of treating pulmonary arterial hypertension according to claim 10, wherein the dry powder composition is provided in a single cartridge containing 8 μg, 16 μg, 24 μg, 32 μg, 64 μg, or 80 μg of treprostinil.
14. 11. The method of claim 10, wherein the dry powder composition is administered in a single inhalation from the dry powder inhaler in less than 10 seconds and the treprostinil reaches a Tmax in the patient's blood in less than about 10 minutes.
15. 11. The method of claim 10, wherein the patient is administered the dry powder formulation twice daily.
16. 1. A method for producing an inhalable dry powder composition comprising the steps of: preparing a suspension of fine crystalline particles of (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine in aqueous ammonia and combining with an acetic acid solution in a high shear mixer at a temperature ranging from 13° C. to about 20° C. while mixing in the high shear mixer to form a suspension; washing the suspension with water, pelletizing the suspension in a freeze granulator, and drying the suspension in a freeze dryer to recover the microcrystalline particles of the diketopiperazine; resuspending the microcrystalline particles of the diketopiperazine in a solution of deionized water and ethanol, preparing a hydrophobic compound in about 70% to about 100% ethanol solution, adding said solution to the suspension with mixing, and drying the suspension; A method comprising:
17. 17. The method of claim 16, wherein the hydrophobic compound is treprostinil, a derivative thereof, or an analog thereof.
18. 17. The method of claim 16, wherein the resuspending step comprises drying crystalline particles of diketopiperazine in a solution of deionized water and alcohol containing from about 0.2% to about 2% solids in the suspension, or from about 1% to about 4% solids in the suspension, or from about 1% to about 10% solids in the suspension.
Citation Information
Patent Citations
Diketopiperazine microparticles having a specified specific surface area
JP2012530064A
Microcrystalline diketopiperazine compositions and methods
JP2016515522A
Dry powder inhaler
JP2019504684A
Dry powder treprostinil for treating pulmonary hypertension
JP2019519489A
Compositions and methods for inhalation
JP2021527058A
